BEONE MEDICINES LTD-ADR (ONC) Stock News

USA - NASDAQ:ONC - US07725L1026 - ADR

318.59 USD

+2.17 (+0.69%)

Last: 10/20/2025, 8:08:50 PM

318.59 USD

0 (0%)

After Hours: 10/20/2025, 8:08:50 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ONC Latest News, Press Relases and Analysis

All

Press Releases

11 hours ago - By: Benzinga - Mentions: MRK SMMT

What's Going On With Summit Therapeutics Stock On Monday?

15 hours ago - By: BeOne Medicines Ltd.

BeOne Medicines Presents New Data on TEVIMBRA in Lung Cancer at ESMO 2025

8 days ago - By: BeOne Medicines Ltd.

BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA

12 days ago - By: Benzinga

Where BeOne Medicines Stands With Analysts

a month ago - By: Investor's Business Daily - Mentions: PFE NYT LLY ZLAB ...

China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order

3 months ago - By: The Motley Fool

BeOne Medicines (ONC) Q2 EPS Soars 924%

2 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)

2 months ago - By: Yahoo Finance

BeOne Medicines Ltd. (ONC) Unveils Promising Breast Cancer Therapies at ASCO 2025

2 months ago - By: BeOne Medicines Ltd.

European Commission Approves TEVIMBRA® as Neoadjuvant/Adjuvant NSCLC Treatment Ahead of Late-Breaking Data Presentation at WCLC 2025

2 months ago - By: BeOne Medicines Ltd.

BeOne to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

2 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million

2 months ago - By: BeOne Medicines Ltd.

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

3 months ago - By: Zacks Investment Research

BeOne Medicines Ltd. - Sponsored ADR (ONC) Reports Q2 Earnings: What Key Metrics Have to Say

3 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Announces Second Quarter 2025 Financial Results and Business Updates

3 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Receives PRIME Designation from the European Medicines Agency for BGB-16673 in Waldenstrom’s Macroglobulinemia

3 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Receives Positive CHMP Opinion for TEVIMBRA® in Neoadjuvant/Adjuvant NSCLC Treatment

3 months ago - By: Yahoo Finance

BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra

3 months ago - By: BeOne Medicines Ltd.

BeOne Medicines to Announce Second Quarter 2025 Financial Results on August 6

3 months ago - By: BeOne Medicines Ltd.

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma

4 months ago - By: Yahoo Finance - Mentions: MS JPM

BeOne Medicines price target raised to $330 from $313 at Morgan Stanley

4 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Showcases Groundbreaking Oncology Pipeline at R&D Day

4 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Receives Positive CHMP Opinion for Tablet Formulation of BRUKINSA®

4 months ago - By: BeOne Medicines Ltd.

BeOne Medicines Showcases Breakthrough Data in CLL and MCL at EHA 2025